Compare Summit Therapeutics Inc (SMMT) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Invesco S&P 500 Low Volatility ETF trades at $72.14 (market cap $6.94B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| SMMT | SPLV | |
|---|---|---|
Market Cap | $13.71B | $6.94B |
Volume | 6,173,057 | 1,663,703 |
Sector | Health | — |
52-Week High | $26.38 | $77.97 |
52-Week Low | $12.43 | $70.30 |
Typical Hold Time | 16 Days | 123 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
SPLV trades at $71.97, up 1.05% today, but faces bearish technical signals with moving averages indicating selling pressure. The ETF's sector allocation to Utilities, Real Estate, and Financials has caused it to lag the S&P 500's performance. Recent dividend payments of $0.14 per share were distributed in July and September 2026.
The outlook remains neutral with valuation concerns at a 19.5x P/E ratio. Key risks include sector concentration and macroeconomic sensitivity, while potential stability during market volatility offers defensive appeal. Current technical support sits at $70 with resistance at $73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
